Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03398135




Registration number
NCT03398135
Ethics application status
Date submitted
8/01/2018
Date registered
12/01/2018
Date last updated
8/10/2024

Titles & IDs
Public title
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis
Secondary ID [1] 0 0
2016-004676-22
Secondary ID [2] 0 0
M16-066
Universal Trial Number (UTN)
Trial acronym
COMMAND
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ulcerative Colitis (UC) 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - risankizumab
Treatment: Drugs - placebo for risankizumab

Placebo comparator: Substudy 1: Double-blind Placebo - Participants randomized to receive placebo for risankizumab administered by subcutaneous (SC) injection.

Experimental: Substudy 1: Double-blind Risankizumab Dose 1 - Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.

Experimental: Substudy 1: Double-blind Risankizumab Dose 2 - Participants randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection.

Experimental: Substudy 2: Open-label (OL) Clinical Assessment Risankizumab - Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.

Experimental: Substudy 2: OL Therapeutic Drug Monitoring Risankizumab - Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.

Experimental: Substudy 3: OL Extension Risankizumab - Participants who completed Sub-study 1 or 2 receive open-label risankizumab in Sub-study 3.

Experimental: OL Continuous Treatment Extension - Dose 1 - Participants who complete Sub-study 3 and continue to tolerate and derive benefit from receiving risankizumab, will continue to receive risankizumab based on their assignment during Sub-study 3. Participants completing Sub-study 3 without receiving risankizumab rescue therapy in any sub-study will receive risankizumab Dose 1 administered by subcutaneous (SC) injection.

Experimental: OL Continuous Treatment Extension - Dose 2 - Participants who complete Sub-study 3 and continue to tolerate and derive benefit from receiving risankizumab, will continue to receive risankizumab based on their assignment during Sub-study 3. Participants completing Sub-study 3 and received risankizumab rescue therapy in any sub-study will receive risankizumab Dose 2 administered by subcutaneous (SC) injection.


Treatment: Drugs: risankizumab
subcutaneous (SC) injection

Treatment: Drugs: placebo for risankizumab
subcutaneous (SC) injection
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Sub-Study 1: Percentage of Participants Achieving Clinical Remission per Adapted Mayo Score
Timepoint [1] 0 0
Week 52
Primary outcome [2] 0 0
Percentage of Participants with Adverse Events (AE)
Timepoint [2] 0 0
Up to Week 300
Secondary outcome [1] 0 0
Sub-Study 1: Percentage of Participants Achieving Endoscopic Improvement
Timepoint [1] 0 0
Week 52
Secondary outcome [2] 0 0
Sub-Study 1: Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement
Timepoint [2] 0 0
Week 52
Secondary outcome [3] 0 0
Sub-Study 1: Percentage of Participants Achieving Endoscopic Remission
Timepoint [3] 0 0
Week 52
Secondary outcome [4] 0 0
Sub-Study 1: Percentage of Participants with Clinical Remission per Adapted Mayo Score in Participants with no Corticosteroid Use for 90 days
Timepoint [4] 0 0
Week 52
Secondary outcome [5] 0 0
Sub-Study 1: Percentage of Participants with Clinical Remission per Adapted Mayo Score in Participants with a Clinical Remission at Week 0
Timepoint [5] 0 0
Week 52
Secondary outcome [6] 0 0
Sub-Study 1: Percentage of Participants Achieving No Bowel Urgency
Timepoint [6] 0 0
Week 52
Secondary outcome [7] 0 0
Sub-Study 1: Percentage of Participants Achieving No Abdominal Pain
Timepoint [7] 0 0
Week 52
Secondary outcome [8] 0 0
Sub-Study 1: Percentage of Participants Achieving Histologic-Endoscopic Mucosal Remission
Timepoint [8] 0 0
Week 52
Secondary outcome [9] 0 0
Sub-Study 1: Percentage of Participants Achieving Endoscopic Improvement in Participants with Endoscopic Improvement at Week 0
Timepoint [9] 0 0
Week 52
Secondary outcome [10] 0 0
Sub-Study 1: Percentage of Participants Achieving Clinical Response per Adapted Mayo Score
Timepoint [10] 0 0
Week 52
Secondary outcome [11] 0 0
Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
Timepoint [11] 0 0
Week 0 to Week 52
Secondary outcome [12] 0 0
Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)
Timepoint [12] 0 0
Baseline (Week 0) to Week 52
Secondary outcome [13] 0 0
Sub-Study 1: Percentage of Participants Achieving No Nocturnal Bowel Movements
Timepoint [13] 0 0
Week 52
Secondary outcome [14] 0 0
Sub-Study 1: Percentage of Participants Achieving No Tenesmus
Timepoint [14] 0 0
Week 52
Secondary outcome [15] 0 0
Sub-Study 1: Change in Number of Fecal Incontinence Episodes per Week
Timepoint [15] 0 0
Baseline (Week 0) to Week 52
Secondary outcome [16] 0 0
Sub-Study 1: Change in Number of Days per Week with Sleep Interrupted due to UC Symptoms
Timepoint [16] 0 0
Baseline (Week 0) to Week 52
Secondary outcome [17] 0 0
Sub-Study 1: Percentage of Participants with Exposure Adjusted Occurrence of Ulcerative Colitis (UC) Related Hospitalization
Timepoint [17] 0 0
Through Week 52

Eligibility
Key inclusion criteria
- Participants who have completed Study M16-067 and have achieved clinical response as defined in the protocol.
Minimum age
16 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participants who have a known hypersensitivity to risankizumab or the excipients of any of the study drugs or the ingredients of chinese hamster ovary (CHO) or had an adverse event (AE) during Studies M16-067 that in the Investigator's judgment makes the participant unsuitable for this study.
* Participant is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
* Participant is not in compliance with prior and concomitant medication requirements throughout Studies M16-067.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/08/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
25/09/2028
Actual
Sample size
Target
Accrual to date
Final
1242
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
North Dakota
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oklahoma
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
South Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Tennessee
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
Utah
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
Argentina
State/province [27] 0 0
Ciudad Autonoma De Buenos Aires
Country [28] 0 0
Argentina
State/province [28] 0 0
Santa Fe
Country [29] 0 0
Argentina
State/province [29] 0 0
Tucuman
Country [30] 0 0
Argentina
State/province [30] 0 0
Cordoba
Country [31] 0 0
Austria
State/province [31] 0 0
Niederoesterreich
Country [32] 0 0
Austria
State/province [32] 0 0
Oberoesterreich
Country [33] 0 0
Austria
State/province [33] 0 0
Steiermark
Country [34] 0 0
Austria
State/province [34] 0 0
Wien
Country [35] 0 0
Austria
State/province [35] 0 0
Salzburg
Country [36] 0 0
Belgium
State/province [36] 0 0
Bruxelles-Capitale
Country [37] 0 0
Belgium
State/province [37] 0 0
Limburg
Country [38] 0 0
Belgium
State/province [38] 0 0
Namur
Country [39] 0 0
Belgium
State/province [39] 0 0
Vlaams-Brabant
Country [40] 0 0
Belgium
State/province [40] 0 0
West-Vlaanderen
Country [41] 0 0
Belgium
State/province [41] 0 0
Liege
Country [42] 0 0
Brazil
State/province [42] 0 0
Goias
Country [43] 0 0
Brazil
State/province [43] 0 0
La Spezia
Country [44] 0 0
Brazil
State/province [44] 0 0
Parana
Country [45] 0 0
Brazil
State/province [45] 0 0
Rio Grande Do Sul
Country [46] 0 0
Brazil
State/province [46] 0 0
Sao Paulo
Country [47] 0 0
Bulgaria
State/province [47] 0 0
Smolyan
Country [48] 0 0
Bulgaria
State/province [48] 0 0
Sofia
Country [49] 0 0
Bulgaria
State/province [49] 0 0
Sliven
Country [50] 0 0
Canada
State/province [50] 0 0
Alberta
Country [51] 0 0
Canada
State/province [51] 0 0
British Columbia
Country [52] 0 0
Canada
State/province [52] 0 0
Ontario
Country [53] 0 0
Canada
State/province [53] 0 0
Prince Edward Island
Country [54] 0 0
Canada
State/province [54] 0 0
Quebec
Country [55] 0 0
Chile
State/province [55] 0 0
Aisen Del General Carlos Ibanez Del Campo
Country [56] 0 0
Chile
State/province [56] 0 0
Araucania
Country [57] 0 0
Chile
State/province [57] 0 0
Region Metropolitana De Santiago
Country [58] 0 0
China
State/province [58] 0 0
Anhui
Country [59] 0 0
China
State/province [59] 0 0
Beijing
Country [60] 0 0
China
State/province [60] 0 0
Guangdong
Country [61] 0 0
China
State/province [61] 0 0
Guizhou
Country [62] 0 0
China
State/province [62] 0 0
Hebei
Country [63] 0 0
China
State/province [63] 0 0
Hubei
Country [64] 0 0
China
State/province [64] 0 0
Jiangsu
Country [65] 0 0
China
State/province [65] 0 0
Jiangxi
Country [66] 0 0
China
State/province [66] 0 0
Jilin
Country [67] 0 0
China
State/province [67] 0 0
Liaoning
Country [68] 0 0
China
State/province [68] 0 0
Ningxia
Country [69] 0 0
China
State/province [69] 0 0
Shaanxi
Country [70] 0 0
China
State/province [70] 0 0
Shanghai
Country [71] 0 0
China
State/province [71] 0 0
Shanxi
Country [72] 0 0
China
State/province [72] 0 0
Sichuan
Country [73] 0 0
China
State/province [73] 0 0
Zhejiang
Country [74] 0 0
Colombia
State/province [74] 0 0
Antioquia
Country [75] 0 0
Colombia
State/province [75] 0 0
Cordoba
Country [76] 0 0
Croatia
State/province [76] 0 0
Grad Zagreb
Country [77] 0 0
Croatia
State/province [77] 0 0
Istarska Zupanija
Country [78] 0 0
Croatia
State/province [78] 0 0
Splitsko-dalmatinska Zupanija
Country [79] 0 0
Czechia
State/province [79] 0 0
Jihomoravsky Kraj
Country [80] 0 0
Czechia
State/province [80] 0 0
Praha 17
Country [81] 0 0
Czechia
State/province [81] 0 0
Brno
Country [82] 0 0
Denmark
State/province [82] 0 0
Hovedstaden
Country [83] 0 0
Denmark
State/province [83] 0 0
Sjælland
Country [84] 0 0
Denmark
State/province [84] 0 0
Syddanmark
Country [85] 0 0
Egypt
State/province [85] 0 0
Al Uqsur
Country [86] 0 0
Egypt
State/province [86] 0 0
Alexandria
Country [87] 0 0
Egypt
State/province [87] 0 0
Cairo
Country [88] 0 0
France
State/province [88] 0 0
Alpes-Maritimes
Country [89] 0 0
France
State/province [89] 0 0
Bouches-du-Rhone
Country [90] 0 0
France
State/province [90] 0 0
Gironde
Country [91] 0 0
France
State/province [91] 0 0
Herault
Country [92] 0 0
France
State/province [92] 0 0
Ile-de-France
Country [93] 0 0
France
State/province [93] 0 0
Loire
Country [94] 0 0
France
State/province [94] 0 0
Meurthe-et-Moselle
Country [95] 0 0
France
State/province [95] 0 0
Somme
Country [96] 0 0
France
State/province [96] 0 0
Nantes
Country [97] 0 0
Germany
State/province [97] 0 0
Baden-Wuerttemberg
Country [98] 0 0
Germany
State/province [98] 0 0
Bayern
Country [99] 0 0
Germany
State/province [99] 0 0
Hessen
Country [100] 0 0
Germany
State/province [100] 0 0
Nordrhein-Westfalen
Country [101] 0 0
Germany
State/province [101] 0 0
Saarland
Country [102] 0 0
Germany
State/province [102] 0 0
Sachsen
Country [103] 0 0
Germany
State/province [103] 0 0
Schleswig-Holstein
Country [104] 0 0
Germany
State/province [104] 0 0
Berlin
Country [105] 0 0
Germany
State/province [105] 0 0
Braunschweig
Country [106] 0 0
Germany
State/province [106] 0 0
Regensburg
Country [107] 0 0
Greece
State/province [107] 0 0
Attiki
Country [108] 0 0
Greece
State/province [108] 0 0
Evrytania
Country [109] 0 0
Greece
State/province [109] 0 0
Kriti
Country [110] 0 0
Greece
State/province [110] 0 0
Athens
Country [111] 0 0
Greece
State/province [111] 0 0
Thessaloniki
Country [112] 0 0
Israel
State/province [112] 0 0
H_efa
Country [113] 0 0
Israel
State/province [113] 0 0
HaDarom
Country [114] 0 0
Israel
State/province [114] 0 0
Tel-Aviv
Country [115] 0 0
Israel
State/province [115] 0 0
Yerushalayim
Country [116] 0 0
Israel
State/province [116] 0 0
Haifa
Country [117] 0 0
Italy
State/province [117] 0 0
Genova
Country [118] 0 0
Italy
State/province [118] 0 0
Milano
Country [119] 0 0
Italy
State/province [119] 0 0
Roma
Country [120] 0 0
Italy
State/province [120] 0 0
Verona
Country [121] 0 0
Italy
State/province [121] 0 0
Bologna
Country [122] 0 0
Italy
State/province [122] 0 0
Catania
Country [123] 0 0
Italy
State/province [123] 0 0
Catanzaro
Country [124] 0 0
Italy
State/province [124] 0 0
Modena
Country [125] 0 0
Italy
State/province [125] 0 0
Rome
Country [126] 0 0
Japan
State/province [126] 0 0
Aichi
Country [127] 0 0
Japan
State/province [127] 0 0
Aomori
Country [128] 0 0
Japan
State/province [128] 0 0
Chiba
Country [129] 0 0
Japan
State/province [129] 0 0
Fukuoka
Country [130] 0 0
Japan
State/province [130] 0 0
Gifu
Country [131] 0 0
Japan
State/province [131] 0 0
Gunma
Country [132] 0 0
Japan
State/province [132] 0 0
Hiroshima
Country [133] 0 0
Japan
State/province [133] 0 0
Hokkaido
Country [134] 0 0
Japan
State/province [134] 0 0
Hyogo
Country [135] 0 0
Japan
State/province [135] 0 0
Ishikawa
Country [136] 0 0
Japan
State/province [136] 0 0
Kagoshima
Country [137] 0 0
Japan
State/province [137] 0 0
Kanagawa
Country [138] 0 0
Japan
State/province [138] 0 0
Mie
Country [139] 0 0
Japan
State/province [139] 0 0
Miyagi
Country [140] 0 0
Japan
State/province [140] 0 0
Nagasaki
Country [141] 0 0
Japan
State/province [141] 0 0
Nara
Country [142] 0 0
Japan
State/province [142] 0 0
Osaka
Country [143] 0 0
Japan
State/province [143] 0 0
Saga
Country [144] 0 0
Japan
State/province [144] 0 0
Saitama
Country [145] 0 0
Japan
State/province [145] 0 0
Shiga
Country [146] 0 0
Japan
State/province [146] 0 0
Shizuoka
Country [147] 0 0
Japan
State/province [147] 0 0
Tokyo
Country [148] 0 0
Japan
State/province [148] 0 0
Wakayama
Country [149] 0 0
Japan
State/province [149] 0 0
Yamagata
Country [150] 0 0
Japan
State/province [150] 0 0
Yamaguchi
Country [151] 0 0
Japan
State/province [151] 0 0
Mitaka
Country [152] 0 0
Korea, Republic of
State/province [152] 0 0
Busan Gwang Yeogsi
Country [153] 0 0
Korea, Republic of
State/province [153] 0 0
Daejeon Gwang Yeogsi
Country [154] 0 0
Korea, Republic of
State/province [154] 0 0
Gyeonggido
Country [155] 0 0
Korea, Republic of
State/province [155] 0 0
Gyeongsangnamdo
Country [156] 0 0
Korea, Republic of
State/province [156] 0 0
Seoul Teugbyeolsi
Country [157] 0 0
Korea, Republic of
State/province [157] 0 0
Daegu
Country [158] 0 0
Korea, Republic of
State/province [158] 0 0
Seoul
Country [159] 0 0
Latvia
State/province [159] 0 0
Riga
Country [160] 0 0
Lithuania
State/province [160] 0 0
Kaunas
Country [161] 0 0
Lithuania
State/province [161] 0 0
Vilnius
Country [162] 0 0
Mexico
State/province [162] 0 0
Morelos
Country [163] 0 0
Mexico
State/province [163] 0 0
Yucatan
Country [164] 0 0
Mexico
State/province [164] 0 0
Del. Benito Juárez
Country [165] 0 0
Netherlands
State/province [165] 0 0
Noord-Holland
Country [166] 0 0
Netherlands
State/province [166] 0 0
Zuid-Holland
Country [167] 0 0
New Zealand
State/province [167] 0 0
Bay Of Plenty
Country [168] 0 0
New Zealand
State/province [168] 0 0
Canterbury
Country [169] 0 0
New Zealand
State/province [169] 0 0
Manawatu-Wanganui
Country [170] 0 0
New Zealand
State/province [170] 0 0
Waikato
Country [171] 0 0
New Zealand
State/province [171] 0 0
Wellington
Country [172] 0 0
New Zealand
State/province [172] 0 0
Otago
Country [173] 0 0
Poland
State/province [173] 0 0
Dolnoslaskie
Country [174] 0 0
Poland
State/province [174] 0 0
Kujawsko-pomorskie
Country [175] 0 0
Poland
State/province [175] 0 0
Malopolskie
Country [176] 0 0
Poland
State/province [176] 0 0
Mazowieckie
Country [177] 0 0
Poland
State/province [177] 0 0
Pomorskie
Country [178] 0 0
Poland
State/province [178] 0 0
Slaskie
Country [179] 0 0
Portugal
State/province [179] 0 0
Braga
Country [180] 0 0
Portugal
State/province [180] 0 0
Faro
Country [181] 0 0
Portugal
State/province [181] 0 0
Porto
Country [182] 0 0
Portugal
State/province [182] 0 0
Regiao Autonoma Da Madeira
Country [183] 0 0
Portugal
State/province [183] 0 0
Setubal
Country [184] 0 0
Portugal
State/province [184] 0 0
Coimbra
Country [185] 0 0
Portugal
State/province [185] 0 0
Lisboa
Country [186] 0 0
Puerto Rico
State/province [186] 0 0
Ponce
Country [187] 0 0
Puerto Rico
State/province [187] 0 0
San Juan
Country [188] 0 0
Romania
State/province [188] 0 0
Cluj
Country [189] 0 0
Romania
State/province [189] 0 0
Bucharest
Country [190] 0 0
Romania
State/province [190] 0 0
Timisoara
Country [191] 0 0
Romania
State/province [191] 0 0
Timi?oara
Country [192] 0 0
Russian Federation
State/province [192] 0 0
Kabardino-Balkarskaya Respublika
Country [193] 0 0
Russian Federation
State/province [193] 0 0
Kaliningradskaya Oblast
Country [194] 0 0
Russian Federation
State/province [194] 0 0
Kemerovskaya Oblast
Country [195] 0 0
Russian Federation
State/province [195] 0 0
Kurskaya Oblast
Country [196] 0 0
Russian Federation
State/province [196] 0 0
Leningradskaya Oblast
Country [197] 0 0
Russian Federation
State/province [197] 0 0
Moskovskaya Oblast
Country [198] 0 0
Russian Federation
State/province [198] 0 0
Permskiy Kray
Country [199] 0 0
Russian Federation
State/province [199] 0 0
Sankt-Peterburg
Country [200] 0 0
Russian Federation
State/province [200] 0 0
Tyumenskaya Oblast
Country [201] 0 0
Russian Federation
State/province [201] 0 0
Dzerzhinskiy
Country [202] 0 0
Russian Federation
State/province [202] 0 0
Moscow
Country [203] 0 0
Russian Federation
State/province [203] 0 0
Pushkin
Country [204] 0 0
Russian Federation
State/province [204] 0 0
St. Petersburg
Country [205] 0 0
Russian Federation
State/province [205] 0 0
Ulyanovsk
Country [206] 0 0
Serbia
State/province [206] 0 0
Beograd
Country [207] 0 0
Serbia
State/province [207] 0 0
Pomoravski Okrug
Country [208] 0 0
Serbia
State/province [208] 0 0
Vojvodina
Country [209] 0 0
Singapore
State/province [209] 0 0
Singapore
Country [210] 0 0
Slovakia
State/province [210] 0 0
Bratislavsky Kraj
Country [211] 0 0
Slovakia
State/province [211] 0 0
Nitriansky Kraj
Country [212] 0 0
Slovakia
State/province [212] 0 0
Presovsky Kraj
Country [213] 0 0
Slovenia
State/province [213] 0 0
Ljubljana
Country [214] 0 0
South Africa
State/province [214] 0 0
Free State
Country [215] 0 0
South Africa
State/province [215] 0 0
Gauteng
Country [216] 0 0
South Africa
State/province [216] 0 0
Western Cape
Country [217] 0 0
Spain
State/province [217] 0 0
A Coruna
Country [218] 0 0
Spain
State/province [218] 0 0
Asturias
Country [219] 0 0
Spain
State/province [219] 0 0
Barcelona
Country [220] 0 0
Spain
State/province [220] 0 0
Madrid
Country [221] 0 0
Spain
State/province [221] 0 0
Pontevedra
Country [222] 0 0
Spain
State/province [222] 0 0
Cordoba
Country [223] 0 0
Spain
State/province [223] 0 0
Salamanca
Country [224] 0 0
Spain
State/province [224] 0 0
Sevilla
Country [225] 0 0
Spain
State/province [225] 0 0
Zaragoza
Country [226] 0 0
Sweden
State/province [226] 0 0
Vastra Gotalands Lan
Country [227] 0 0
Sweden
State/province [227] 0 0
Stockholm
Country [228] 0 0
Switzerland
State/province [228] 0 0
Zuerich
Country [229] 0 0
Switzerland
State/province [229] 0 0
Bern
Country [230] 0 0
Taiwan
State/province [230] 0 0
Keelung
Country [231] 0 0
Taiwan
State/province [231] 0 0
Taipei
Country [232] 0 0
Taiwan
State/province [232] 0 0
Taichung
Country [233] 0 0
Taiwan
State/province [233] 0 0
Taoyuan City
Country [234] 0 0
Turkey
State/province [234] 0 0
Istanbul
Country [235] 0 0
Turkey
State/province [235] 0 0
Kayseri
Country [236] 0 0
Turkey
State/province [236] 0 0
Ankara
Country [237] 0 0
Turkey
State/province [237] 0 0
Battalgazi/malatya
Country [238] 0 0
Turkey
State/province [238] 0 0
Bursa
Country [239] 0 0
Turkey
State/province [239] 0 0
Elazig
Country [240] 0 0
Ukraine
State/province [240] 0 0
Ivano-frankivsk
Country [241] 0 0
Ukraine
State/province [241] 0 0
Kherson
Country [242] 0 0
Ukraine
State/province [242] 0 0
Kyiv
Country [243] 0 0
United Kingdom
State/province [243] 0 0
Cambridgeshire
Country [244] 0 0
United Kingdom
State/province [244] 0 0
Devon
Country [245] 0 0
United Kingdom
State/province [245] 0 0
Hampshire
Country [246] 0 0
United Kingdom
State/province [246] 0 0
London, City Of
Country [247] 0 0
United Kingdom
State/province [247] 0 0
Barnsley
Country [248] 0 0
United Kingdom
State/province [248] 0 0
Edinburgh
Country [249] 0 0
United Kingdom
State/province [249] 0 0
Liverpool
Country [250] 0 0
United Kingdom
State/province [250] 0 0
London
Country [251] 0 0
United Kingdom
State/province [251] 0 0
Newcastle upon Tyne
Country [252] 0 0
United Kingdom
State/province [252] 0 0
Tooting

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC.

This study consists of three sub-studies and a Continuous Treatment Extension (CTE): Substudy 1 is a 52-week, randomized, double-blind, placebo-controlled maintenance study; Substudy 2 is 52-week, randomized, exploratory maintenance study; and Substudy 3 is an open-label long-term extension study for participants who completed Substudy 1 or 2, or participants who responded to induction treatment in Study M16-067 with no final endoscopy due to the Covid-19 pandemic or due to the geopolitical conflict in Ukraine and surrounding impacted regions. The CTE is an open-label extension for Substudy 3 completers to ensure continuous treatment with risankizumab until such time that risankizumab becomes commercially available and/or the subject can access treatment locally or can transition to a Continued Treatment for Trial Participants Open-Label Extension study.
Trial website
https://clinicaltrials.gov/study/NCT03398135
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03398135